<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Life Sci</journal-id><journal-id journal-id-type="iso-abbrev">Life Sci</journal-id><journal-title-group><journal-title>Life Sciences</journal-title></journal-title-group><issn pub-type="ppub">0024-3205</issn><issn pub-type="epub">1879-0631</issn><publisher><publisher-name>Elsevier Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">S0024-3205(20)30375-1</article-id><article-id pub-id-type="doi">10.1016/j.lfs.2020.117627</article-id><article-id pub-id-type="publisher-id">117627</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0005"><name><surname>Kandeel</surname><given-names>Mahmoud</given-names></name><email>mkandeel@kfu.edu.sa</email><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0010" ref-type="aff">b</xref><xref rid="cr0005" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author" id="au0010"><name><surname>Al-Nazawi</surname><given-names>Mohammed</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><aff id="af0005"><label>a</label>Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Al-hofuf, 31982, Al-ahsa, Saudi Arabia</aff><aff id="af0010"><label>b</label>Department of Pharmacology, Faculty of Veterinary Medicine, Kafrelshikh University, Kafrelshikh 33516, Egypt</aff></contrib-group><author-notes><corresp id="cr0005"><label>&#x0204e;</label>Corresponding author at: Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Al-hofuf, 31982, Al-ahsa, Saudi Arabia. <email>mkandeel@kfu.edu.sa</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>3</day><month>4</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><day>15</day><month>6</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>3</day><month>4</month><year>2020</year></pub-date><volume>251</volume><fpage>117627</fpage><lpage>117627</lpage><history><date date-type="received"><day>25</day><month>2</month><year>2020</year></date><date date-type="rev-recd"><day>27</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>30</day><month>3</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Elsevier Inc. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier Inc.</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="ab0005"><sec><title>Aims</title><p>In December 2019, the Coronavirus disease-2019 (COVID-19) virus has emerged in Wuhan, China. In this research, the first resolved COVID-19 crystal structure (main protease) was targeted in a virtual screening study by of FDA approved drugs dataset. In addition, a knowledge gap in relations of COVID-19 with the previously known fatal Coronaviruses (CoVs) epidemics, SARS and MERS CoVs, was covered by investigation of sequence statistics and phylogenetics.</p></sec><sec><title>Materials and methods</title><p>Molecular modeling, virtual screening, docking, sequence comparison statistics and phylogenetics of the COVID-19 main protease were investigated.</p></sec><sec><title>Key findings</title><p>COVID-19 Mpro formed a phylogenetic group with SARS CoV that was distant from MERS CoV. The identity% was 96.061 and 51.61 for COVID-19/SARS and COVID-19/MERS CoV sequence comparisons, respectively. The top 20 drugs in the virtual screening studies comprised a broad-spectrum antiviral (ribavirin), anti-hepatitis B virus (telbivudine), two vitamins (vitamin B12 and nicotinamide) and other miscellaneous systemically acting drugs. Of special interest, ribavirin had been used in treating cases of SARS CoV.</p></sec><sec><title>Significance</title><p>The present study provided a comprehensive targeting of the first resolved COVID+19 structure of Mpro and found a suitable save drugs for repurposing against the viral Mpro. Ribavirin, telbivudine, vitamin B12 and nicotinamide can be combined and used for COVID treatment. This initiative relocates already marketed and approved safe drugs for potential use in COVID-treatment.</p></sec></abstract><kwd-group id="ks0005"><title>Abbreviations</title><kwd>COVID-19, Coronavirus disease 2019</kwd><kwd>2019-nCoV, 2019 New Coronavirus</kwd><kwd>MERS CoV, Middle East Respiratory Syndrome Coronavirus</kwd><kwd>ORF, open reading frames</kwd><kwd>S, spike protein</kwd><kwd>E, envelope</kwd><kwd>M, membrane protein</kwd><kwd>N, nucleocapsid</kwd><kwd>3CLpro, 3-C-like protease</kwd><kwd>SARS, Severe Acute Respiratory Syndrome CoV</kwd></kwd-group><kwd-group id="ks0010"><title>Keywords</title><kwd>COVID-19, 2019-nCoV</kwd><kwd>2019-Novel Coronavirus</kwd><kwd>Wuhan Coronavirus</kwd><kwd>Main protease</kwd><kwd>Molecular modeling</kwd></kwd-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0005">Recently, a severe and highly contagious viral disease was evolved in Wuhan, China [<xref rid="bb0005" ref-type="bibr">1</xref>]. The causative agent was detected to be a new coronavirus and termed as Coronavirus disease 2019 (COVID-19).</p><p id="p0010">Coronavirus has been associated with several infectious epidemics with major health hazard concerns. In 2000&#x02013;2004, the Severe Acute Respiratory Syndrome CoV (SARS CoV) was evolved [<xref rid="bb0010" ref-type="bibr">2</xref>]. The source of the infection was recorded from animal origins, including a bat as an intermediate host [<xref rid="bb0015" ref-type="bibr">3</xref>]. About a decade later, the Middle East Respiratory Syndrome Coronavirus (MERS CoV) was diagnosed in Saudi Arabia [<xref rid="bb0020" ref-type="bibr">4</xref>]. Soon after the emergence of SARS and MERS CoVs, they spread to outside of the countries of its origin, causing major world-wide concerns [<xref rid="bb0025" ref-type="bibr">5</xref>,<xref rid="bb0030" ref-type="bibr">6</xref>]. Lastly, COVID-19 emerged in Wuhan, China. The first isolation was related to an animal market and human-to-human transmission was recorded [<xref rid="bb0035" ref-type="bibr">7</xref>].</p><p id="p0015">The coronavirus polyprotein encodes two proteases, which share in its processing and release of the translated non-structural proteins (NSPs), the main protease is called 3-C-like protease (M-pro) and a papain-like protease (Plpro) [<xref rid="bb0040" ref-type="bibr">8</xref>]. Both Plpro and Mpro were vital targets for drug discovery studies against the recent coronavirus epidemics including SARS and MERS CoV [<xref rid="bb0045" ref-type="bibr">[9]</xref>, <xref rid="bb0050" ref-type="bibr">[10]</xref>, <xref rid="bb0055" ref-type="bibr">[11]</xref>, <xref rid="bb0060" ref-type="bibr">[12]</xref>].</p><p id="p0020">The first and the only available crystal structure of COVID-19 proteins is Mpro, which was published in February 2020 (PDB ID <ext-link ext-link-type="uri" xlink:href="pdb:6lu7" id="ir0005">6lu7</ext-link>). In this study, the first virtual screening study against the first known COVID-19 was performed. The obtained results will help in the repurposing of already approved drugs to combat the recent dangerous COVID-19.</p></sec><sec id="s0010"><label>2</label><title>Methods</title><sec id="s0015"><label>2.1</label><title>Retrieval of Mpro sequences</title><p id="p0025">The NCBI GenBank or GISAID (<ext-link ext-link-type="uri" xlink:href="https://www.gisaid.org/" id="ir0010">https://www.gisaid.org/</ext-link>) were used to obtain the COVID-19 sequences. SARS CoV and MERS CoV sequences were obtained from the GenBank.</p></sec><sec id="s0020"><label>2.2</label><title>Sequence alignment and multiple sequence comparisons</title><p id="p0030">Pairwise and multiple sequence comparisons of Mpro were done using CLC genomics software (Qiagen Inc., USA). The sequence comparison matrix was generated, including the number of gaps, number of different residues and identity %.</p></sec><sec id="s0025"><label>2.3</label><title>Construction of phylogenetic tree</title><p id="p0035">The aligned sequences file was used to generate, a phylogenetic tree by using the neighbor joining method implemented in CLC genomics workbench software.</p></sec><sec id="s0030"><label>2.4</label><title>Construction of drugs dataset and ligand preparation</title><p id="p0040">FDA approved drugs dataset was retrieved from Selleckchem Inc. (WA, USA). All compounds were imported to Ligprep software, deslated and 3D optimized using OPLS2005 force field.</p></sec><sec id="s0035"><label>2.5</label><title>COVID-19 Mpro protein preparation</title><p id="p0045">Virtual screening was implemented by using the published crystal structure of COVID-19 Mpro (PDB ID <ext-link ext-link-type="uri" xlink:href="pdb:6lu7" id="ir0015">6lu7</ext-link>). The protein preparation module in Maestro software package (Schrodinger LLC, NY, USA) was used to optimize the protein structure for docking. Water and other nonspecific molecules were removed, the protein was protonated to add polar hydrogens, the structure was optimized at cellular pH conditions, and the structure energy minimized using OPLS2005 force field. The docking grid was generated by using the co-crystalised ligand as the center for docking box of 20&#x000a0;&#x000c5; size.</p></sec><sec id="s0040"><label>2.6</label><title>Virtual screening</title><p id="p0050">The Schrodinger glide docking module was used for virtual screening. In order to get accurate results, the standard precision (SP docking) was selected [<xref rid="bb9000" ref-type="bibr">27</xref>,<xref rid="bb8000" ref-type="bibr">28</xref>]. The output results were ordered by docking score. In this set, the curcumin was found to be a strong inhibitor of SARS Mpro [<xref rid="bb0065" ref-type="bibr">13</xref>]. The measured IC50 was 0.0235&#x000a0;&#x003bc;M. The obtained docking results were reanalyzed to include a comparison with curcumin. The relative docking scores were calculated for every compound by dividing its score with the docking score curcumin.</p></sec></sec><sec id="s0045"><label>3</label><title>Results and discussion</title><p id="p0055">Molecular modeling, virtual screening and other computational techniques are widely used methods to understand the phylogenetics, molecular aspects of proteins and protein-ligand interactions during drug discovery process [<xref rid="bb0070" ref-type="bibr">[14]</xref>, <xref rid="bb0075" ref-type="bibr">[15]</xref>, <xref rid="bb0080" ref-type="bibr">[16]</xref>, <xref rid="bb0085" ref-type="bibr">[17]</xref>, <xref rid="bb0090" ref-type="bibr">[18]</xref>]. Virtual screening has been used in drug discovery against emerging and fatal diseases including SARS CoV proteases [<xref rid="bb0095" ref-type="bibr">19</xref>,<xref rid="bb0100" ref-type="bibr">20</xref>], Hepatitis C virus RNA-dependent RNA polymerase [<xref rid="bb0105" ref-type="bibr">21</xref>], dengue virus [<xref rid="bb0110" ref-type="bibr">22</xref>] and Ebola virus [<xref rid="bb0115" ref-type="bibr">23</xref>].</p><p id="p0060">In this work, we cover a knowledge gap about the COVID-19 Mpro and its comparison with the two most dangerous coronavirus epidemics, SARS and MERS CoVs. In addition, we used the first resolved COVID-19 crystal structure of Mpro to find suitable binding agents with proved safety. In this context, the FDA approved drugs were the best starting point in the way of repurposing approved and safe drugs against COVID-19.</p><p id="p0065">At first, the Mpro from COVID-19 was compared with SARS and MERS CoVs (<xref rid="f0005" ref-type="fig">Fig. 1</xref>
). Comparing COVID-19 Mpro with SARS Mpro (<xref rid="f0005" ref-type="fig">Fig. 1</xref>A) and MERS CoV Mpro (<xref rid="f0005" ref-type="fig">Fig. 1</xref>B) revealed high degree of conservation between COVID-19 and SARS CoV Mpros and little number of different residues. However, MERS CoV Mpro showed large number of differences and low conservation with COVID-19 Mpro. This was evidenced by the phylogenetic relations (<xref rid="f0005" ref-type="fig">Fig. 1</xref>C), which showed close relation of SARS and COVID-19 Mpros and distant relation to MERS CoV.<fig id="f0005"><label>Fig. 1</label><caption><p>Sequences alignment and phylogenetic relations of Mpro from SARS CoV, MERS CoV and COVID-19. A) Pairwise sequence alignment of COVID-19 and SARS CoVs Mpro. Conserved residues are not highlighted and displayed in black colour. The different residues are highlighted in by red colour B) pairwise sequence comparison of COVID-19 and MERS CoVs. Conserved residues are not highlighted and displayed in black colour. The different residues are highlighted in by red colour. C) the phylogenetic relations of Mpro, the tree was generated after the maximum likelihood. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)</p></caption><alt-text id="al0005">Fig. 1</alt-text><graphic xlink:href="gr1_lrg"/></fig></p><p id="p0070">Statistics of sequences comparison was generated in a pairwise sequence comparison matrix (<xref rid="t0005" ref-type="table">Table 1</xref>
). There was 96.08% identity between COVID-19 and SARS CoV Mpro, while low identity% of 51.61 was detected for COVID-19 and MERS CoV Mpro. The number of COVID-19 amino acid differences was 12 and 153 for SARS CoV and MERS CoV, respectively.<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>Sequence comparison matrix of COVID-19, SARS and MERS CoVs Mpro. The upper diagonal panel shows the number of amino acids differences. The lower diagonal panel shows the identity%.</p></caption><alt-text id="al0015">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th/><th>COVID-19</th><th>SARS CoV</th><th>MERS CoV</th></tr></thead><tbody><tr><td>COVID-19</td><td/><td align="char">12</td><td align="char">150</td></tr><tr><td>SARS CoV</td><td align="char">96.08</td><td/><td align="char">153</td></tr><tr><td>MERS CoV</td><td align="char">51.61</td><td align="char">50.65</td><td/></tr></tbody></table></table-wrap></p><p id="p0075">The results of virtual screening of FDA approved drugs against COVID-Mpro is presented in <xref rid="ec0005" ref-type="supplementary-material">Supplementary Table 1</xref>. The presented parameters include the docking scores, ligand efficiency, lipophilic and hydrogen bonding interactions. The top 20 hits showing the highest docking score are provided in <xref rid="t0010" ref-type="table">Table 2</xref>. The data were presented as a relative value to curcumin (a previously approved SARS Mpro inhibitor). Curcumin docking score was ranked at the 334 position, implying the presence of wide range of expected more powerful binding drugs. Within the top 20 drugs there was 2 antivirals, 2 antituberculous agents, 2 vitamins, 1 anticancer and other miscellaneous systemically acting drugs.</p><p id="p0085">
Among antivirals, ribavirin and telbivudine were ranked at the second and third positions. They showed 2 folds increase in the docking scores, compared with curcumin. Vitamin B12 and nicotinamide were ranked at the 4th and 6th positions.<table-wrap position="float" id="t0010"><label>Table 2</label><caption><p>The top 20 drugs showing the highest docking score.</p></caption><alt-text id="al0020">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Item name</th><th>Formula</th><th>MW</th><th>Relative docking score</th><th>Relative ligand efficiency</th><th>Relative glide lipo</th><th>Relative glide hbond</th><th>Clinical uses</th></tr></thead><tbody><tr><td>Chromocarb</td><td>C10H6O4</td><td align="char">190</td><td align="char">2.08</td><td align="char">4.03</td><td align="char">0.92</td><td align="char">4.80</td><td>Vasoprotective</td></tr><tr><td>Ribavirin</td><td>C8H12N4O5</td><td align="char">244</td><td align="char">2.01</td><td align="char">3.21</td><td align="char">0.37</td><td align="char">4.36</td><td>Antiviral</td></tr><tr><td>Telbivudine</td><td>C10H14N2O5</td><td align="char">242</td><td align="char">2.00</td><td align="char">3.19</td><td align="char">0.44</td><td align="char">6.12</td><td>Hepatitis B virus</td></tr><tr><td>Vitamin B12</td><td>C63H88CoN14O14P</td><td align="char">1355</td><td align="char">1.99</td><td align="char">0.60</td><td align="char">0.49</td><td align="char">9.70</td><td>Vitamin</td></tr><tr><td>Aminophylline</td><td>C16H24N10O4</td><td align="char">420</td><td align="char">1.92</td><td align="char">4.00</td><td align="char">0.46</td><td align="char">3.20</td><td>Bronchodilator</td></tr><tr><td>Nicotinamide</td><td>C6H6N2O</td><td align="char">122</td><td align="char">1.91</td><td align="char">5.76</td><td align="char">0.71</td><td align="char">5.76</td><td>Vitamin</td></tr><tr><td>Triflusal</td><td>C10H7F3O4</td><td align="char">248</td><td align="char">1.87</td><td align="char">2.99</td><td align="char">1.05</td><td align="char">2.53</td><td>Cardiovascular</td></tr><tr><td>Bemegride</td><td>C8H13NO2</td><td align="char">155</td><td align="char">1.83</td><td align="char">4.52</td><td align="char">0.68</td><td align="char">3.88</td><td>CNS stimulant</td></tr><tr><td>Aminosalicylate Sodium</td><td>C7H6NNaO3</td><td align="char">175</td><td align="char">1.80</td><td align="char">4.44</td><td align="char">0.76</td><td align="char">1.60</td><td>Antituberculosis agents</td></tr><tr><td>Pyrazinamide</td><td>C5H5N3O</td><td align="char">123</td><td align="char">1.80</td><td align="char">5.42</td><td align="char">0.52</td><td align="char">4.29</td><td>Antituberculosis agents</td></tr><tr><td>Temozolomide</td><td>C6H6N6O2</td><td align="char">194</td><td align="char">1.79</td><td align="char">3.47</td><td align="char">0.12</td><td align="char">3.20</td><td>Anticancer</td></tr><tr><td>Methazolamide</td><td>C5H8N4O3S2</td><td align="char">236</td><td align="char">1.78</td><td align="char">3.45</td><td align="char">0.00</td><td align="char">5.76</td><td>Glaucoma</td></tr><tr><td>Tioxolone</td><td>C7H4O3S</td><td align="char">168</td><td align="char">1.78</td><td align="char">4.38</td><td align="char">0.92</td><td align="char">3.20</td><td>Anti-acne</td></tr><tr><td>Propylthiouracil</td><td>C7H10N2OS</td><td align="char">170</td><td align="char">1.77</td><td align="char">4.38</td><td align="char">0.56</td><td align="char">3.20</td><td>Antithyroid agent</td></tr><tr><td>Cysteamine HCl</td><td>C2H8ClNS</td><td align="char">114</td><td align="char">1.77</td><td align="char">12.01</td><td align="char">0.00</td><td align="char">2.00</td><td>Nephropathic cystinosis</td></tr><tr><td>methoxamine hydrochloride</td><td>C11H18ClNO3</td><td align="char">248</td><td align="char">1.77</td><td align="char">3.20</td><td align="char">0.10</td><td align="char">5.09</td><td>Alpha-adrenergic agonist</td></tr><tr><td>Zonisamide</td><td>C8H8N2O3S</td><td align="char">212</td><td align="char">1.76</td><td align="char">3.42</td><td align="char">0.47</td><td align="char">3.20</td><td>Anticonvulsant</td></tr><tr><td>(+,-)-Octopamine HCl</td><td>C8H12ClNO2</td><td align="char">190</td><td align="char">1.76</td><td align="char">4.33</td><td align="char">0.09</td><td align="char">5.09</td><td>Adrenergic agonist</td></tr><tr><td>Amiloride hydrochloride</td><td>C6H9Cl2N7O</td><td align="char">266</td><td align="char">1.76</td><td align="char">3.18</td><td align="char">0.30</td><td align="char">6.69</td><td>Diuretic</td></tr></tbody></table></table-wrap></p><p id="p0090">Ribavirin is abroad spectrum antiviral agent acting by induction of mutations in the viral genome, especially in RNA viruses [<xref rid="bb0120" ref-type="bibr">24</xref>]. Ribavirin is officially approved for treating respiratory syncytial virus (RSV) infection and, in combination with interferon &#x003b1;2b for hepatitis C virus [<xref rid="bb0125" ref-type="bibr">25</xref>]. In addition, it was used for treating SARS CoV infections [<xref rid="bb0125" ref-type="bibr">25</xref>]. Given the high similarity of SARS and COVID-19 Mpros, ribavirin might be of a value in treating COVID-19.</p><p id="p0095">Telbivudine is approved for treating hepatitis B virus [<xref rid="bb0130" ref-type="bibr">26</xref>]. The drug is nucleoside analogue and best fits the viral polymerase. The high rank of telbivudine in this study suggests its repurposing for COVID-19 treatment by its binding to Mpro.</p><p id="p0100">In comparison with curcumin, the top 10 ranked compounds showed improved hydrogen bonding profile. There was 1.6&#x02013;9.7 fold increase in hydrogen bonding interactions. In contrast, the hydrophobic interactions were kept constant or lowered.</p><p id="p0105">By inspection of the binding mode of top ranked drugs, hydrogen bonding and hydrophobic interactions were the driving force for binding (<xref rid="f0010" ref-type="fig">Fig. 2</xref>
). Ribavirin formed two hydrogen bonds with the backbone of THR25 and side chain of GLN189 (<xref rid="f0010" ref-type="fig">Fig. 2</xref>B and C). Telbivudine formed two hydrogen bonds with SER49 and GLV189 (<xref rid="f0010" ref-type="fig">Fig. 2</xref>D and E).<fig id="f0010"><label>Fig. 2</label><caption><p>Virtual screening and docking of FDA drugs with COVID-19 Mpro. A) The top 40 compounds docked into the Mpro binding site. B) The docking site of ribavirin C) The ligand interactions of ribavirin with Mpro D) The site of docking of telbivudine E) The ligand interactions of telbivudine with Mpro. Hydrogen bonds are shown in purple arrows, hydrophobic interactions in grey circles. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)</p></caption><alt-text id="al0010">Fig. 2</alt-text><graphic xlink:href="gr2_lrg"/></fig></p><p id="p0110">In conclusion, molecular modeling tools were used to compare the Mpro of the recently evolved COVID-19 and the previous two coronavirus epidemics SARS and MERS CoV. COVID-19 Mpro was more phylogenetically related to SARS Mpro. After a virtual screening capmain against COVID-19 Mpro, a set of antivirals, vitamins, antimicrobials, and other systemically acting drugs were more potent binding with COVID-19 Mpro, compared with curcumin (known Mpro inhibitor). The repurposing of ribavirin, telbivudine, vitamin B12 and nicotinamide is suggested.</p><p id="p0115">The following is the supplementary data related to this article.<supplementary-material content-type="local-data" id="ec0005"><caption><title>Supplementary Table 1</title><p>The docking output parameters for FDA approved drugs dataset against SARS-CoV-2 Mpro.</p></caption><media xlink:href="mmc1.xlsx"><alt-text>Supplementary Table 1</alt-text></media></supplementary-material>
</p></sec></body><back><ref-list id="bi0005"><title>References</title><ref id="bb0005"><label>1</label><element-citation publication-type="journal" id="rf0005"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Feng</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name></person-group><article-title>Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission</article-title><source>Sci. China Life Sci.</source><year>2020</year><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">31564034</pub-id></element-citation></ref><ref id="bb0010"><label>2</label><element-citation publication-type="journal" id="rf0010"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>J.</given-names></name><name><surname>Lai</surname><given-names>S.</given-names></name><name><surname>Poon</surname><given-names>L.</given-names></name><name><surname>Guan</surname><given-names>Y.</given-names></name><name><surname>Yam</surname><given-names>L.</given-names></name><name><surname>Lim</surname><given-names>W.</given-names></name></person-group><article-title>Coronavirus as a possible cause of severe acute respiratory syndrome</article-title><source>Lancet</source><volume>361</volume><year>2003</year><fpage>1319</fpage><lpage>1325</lpage><pub-id pub-id-type="pmid">12711465</pub-id></element-citation></ref><ref id="bb0015"><label>3</label><element-citation publication-type="journal" id="rf0015"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Wong</surname><given-names>S.-K.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Kuhn</surname><given-names>J.H.</given-names></name><name><surname>Huang</surname><given-names>I.-C.</given-names></name><name><surname>Choe</surname><given-names>H.</given-names></name></person-group><article-title>Animal origins of the severe acute respiratory syndrome coronavirus: insight from ACE2-S-protein interactions</article-title><source>J. Virol.</source><volume>80</volume><year>2006</year><fpage>4211</fpage><lpage>4219</lpage><pub-id pub-id-type="pmid">16611880</pub-id></element-citation></ref><ref id="bb0020"><label>4</label><element-citation publication-type="journal" id="rf0020"><person-group person-group-type="author"><name><surname>Zaki</surname><given-names>A.M.</given-names></name><name><surname>van Boheemen</surname><given-names>S.</given-names></name><name><surname>Bestebroer</surname><given-names>T.M.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name><surname>Fouchier</surname><given-names>R.A.</given-names></name></person-group><article-title>Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia</article-title><source>N. Engl. J. Med.</source><volume>367</volume><year>2012</year><fpage>1814</fpage><lpage>1820</lpage><pub-id pub-id-type="pmid">23075143</pub-id></element-citation></ref><ref id="bb0025"><label>5</label><element-citation publication-type="journal" id="rf0025"><person-group person-group-type="author"><name><surname>Desenclos</surname><given-names>J.-C.</given-names></name><name><surname>Van der Werf</surname><given-names>S.</given-names></name><name><surname>Bonmarin</surname><given-names>I.</given-names></name><name><surname>Levy-Bruhl</surname><given-names>D.</given-names></name><name><surname>Yazdanpanah</surname><given-names>Y.</given-names></name><name><surname>Hoen</surname><given-names>B.</given-names></name></person-group><article-title>Introduction of SARS in France, March&#x02013;April, 2003</article-title><source>Emerg. Infect. Dis.</source><volume>10</volume><year>2004</year><fpage>195</fpage><pub-id pub-id-type="pmid">15030682</pub-id></element-citation></ref><ref id="bb0030"><label>6</label><element-citation publication-type="journal" id="rf0030"><person-group person-group-type="author"><name><surname>Guarner</surname><given-names>J.</given-names></name></person-group><article-title>Three emerging coronaviruses in two decades: the story of SARS, MERS, and now COVID-19</article-title><source>Am. J. Clin. Pathol.</source><volume>153</volume><issue>4</issue><year>2020</year><fpage>420</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1093/ajcp/aqaa029</pub-id><pub-id pub-id-type="pmid">32053148</pub-id></element-citation></ref><ref id="bb0035"><label>7</label><element-citation publication-type="journal" id="rf0035"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>Y.</given-names></name><name><surname>Shang</surname><given-names>J.</given-names></name><name><surname>Graham</surname><given-names>R.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS</article-title><source>J. Virol.</source><volume>94</volume><issue>7</issue><year>2020</year><fpage>e00127</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1128/JVI.00127-20</pub-id><pub-id pub-id-type="pmid">31996437</pub-id></element-citation></ref><ref id="bb0040"><label>8</label><element-citation publication-type="journal" id="rf0040"><person-group person-group-type="author"><name><surname>Hilgenfeld</surname><given-names>R.</given-names></name></person-group><article-title>From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design</article-title><source>FEBS J.</source><volume>281</volume><year>2014</year><fpage>4085</fpage><lpage>4096</lpage><pub-id pub-id-type="pmid">25039866</pub-id></element-citation></ref><ref id="bb0045"><label>9</label><element-citation publication-type="journal" id="rf0045"><person-group person-group-type="author"><name><surname>Kandeel</surname><given-names>M.</given-names></name><name><surname>Altaher</surname><given-names>A.</given-names></name><name><surname>Alnazawi</surname><given-names>M.</given-names></name></person-group><article-title>Molecular dynamics and inhibition of MERS CoV papain-like protease by small molecule imidazole and aminopurine derivatives</article-title><source>Lett. Drug Des. Discov.</source><volume>16</volume><year>2019</year><fpage>584</fpage><lpage>591</lpage></element-citation></ref><ref id="bb0050"><label>10</label><element-citation publication-type="journal" id="rf0050"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.-H.</given-names></name><name><surname>Hu</surname><given-names>C.-Y.</given-names></name><name><surname>Wu</surname><given-names>N.-P.</given-names></name><name><surname>Yao</surname><given-names>H.-P.</given-names></name><name><surname>Li</surname><given-names>L.-J.</given-names></name></person-group><article-title>Molecular characteristics, functions, and related pathogenicity of MERS-CoV proteins</article-title><source>Engineering</source><volume>5</volume><issue>5</issue><year>2019</year><fpage>940</fpage><lpage>947</lpage><pub-id pub-id-type="doi">10.1016/j.eng.2018.11.035</pub-id><pub-id pub-id-type="pmid">32288963</pub-id></element-citation></ref><ref id="bb0055"><label>11</label><element-citation publication-type="journal" id="rf0055"><person-group person-group-type="author"><name><surname>Pillaiyar</surname><given-names>T.</given-names></name><name><surname>Meenakshisundaram</surname><given-names>S.</given-names></name><name><surname>Manickam</surname><given-names>M.</given-names></name></person-group><article-title>Recent discovery and development of inhibitors targeting coronaviruses</article-title><source>Drug Discov. Today</source><year>2020</year></element-citation></ref><ref id="bb0060"><label>12</label><element-citation publication-type="journal" id="rf0060"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A.</given-names></name><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>Azhar</surname><given-names>E.I.</given-names></name><name><surname>Hui</surname><given-names>D.S.</given-names></name><name><surname>Yuen</surname><given-names>K.-Y.</given-names></name></person-group><article-title>Coronaviruses&#x02014;drug discovery and therapeutic options</article-title><source>Nat. Rev. Drug Discov.</source><volume>15</volume><year>2016</year><fpage>327</fpage><pub-id pub-id-type="pmid">26868298</pub-id></element-citation></ref><ref id="bb0065"><label>13</label><element-citation publication-type="journal" id="rf0065"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>C.-C.</given-names></name><name><surname>Kuo</surname><given-names>Y.-H.</given-names></name><name><surname>Jan</surname><given-names>J.-T.</given-names></name><name><surname>Liang</surname><given-names>P.-H.</given-names></name><name><surname>Wang</surname><given-names>S.-Y.</given-names></name><name><surname>Liu</surname><given-names>H.-G.</given-names></name></person-group><article-title>Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus</article-title><source>J. Med. Chem.</source><volume>50</volume><year>2007</year><fpage>4087</fpage><lpage>4095</lpage><pub-id pub-id-type="pmid">17663539</pub-id></element-citation></ref><ref id="bb0070"><label>14</label><element-citation publication-type="journal" id="rf0070"><person-group person-group-type="author"><name><surname>Altaher</surname><given-names>Y.</given-names></name><name><surname>Kandeel</surname><given-names>M.</given-names></name></person-group><article-title>Molecular analysis of some camel cytochrome P450 enzymes reveals lower evolution and drug-binding properties</article-title><source>J. Biomol. Struct. Dyn.</source><volume>34</volume><year>2016</year><fpage>115</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">25640974</pub-id></element-citation></ref><ref id="bb0075"><label>15</label><element-citation publication-type="journal" id="rf0075"><person-group person-group-type="author"><name><surname>Altaher</surname><given-names>Y.</given-names></name><name><surname>Nakanishi</surname><given-names>M.</given-names></name><name><surname>Kandeel</surname><given-names>M.</given-names></name></person-group><article-title>Annotation of camel genome for estimation of drug binding power, evolution and adaption of cytochrome P450 1a2</article-title><source>Int. J. Pharmacol.</source><volume>11</volume><year>2015</year><fpage>243</fpage><lpage>247</lpage></element-citation></ref><ref id="bb0080"><label>16</label><element-citation publication-type="journal" id="rf0080"><person-group person-group-type="author"><name><surname>Kandeel</surname><given-names>M.</given-names></name><name><surname>Ando</surname><given-names>T.</given-names></name><name><surname>Kitamura</surname><given-names>Y.</given-names></name><name><surname>Abdel-Aziz</surname><given-names>M.</given-names></name><name><surname>Kitade</surname><given-names>Y.</given-names></name></person-group><article-title>Mutational, inhibitory and microcalorimetric analyses of Plasmodium falciparum TMP kinase. Implications for drug discovery</article-title><source>Parasitology</source><volume>136</volume><year>2009</year><fpage>11</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">19126267</pub-id></element-citation></ref><ref id="bb0085"><label>17</label><element-citation publication-type="journal" id="rf0085"><person-group person-group-type="author"><name><surname>Murgueitio</surname><given-names>M.S.</given-names></name><name><surname>Bermudez</surname><given-names>M.</given-names></name><name><surname>Mortier</surname><given-names>J.</given-names></name><name><surname>Wolber</surname><given-names>G.</given-names></name></person-group><article-title>In silico virtual screening approaches for anti-viral drug discovery</article-title><source>Drug Discov. Today Technol.</source><volume>9</volume><year>2012</year><comment>(e219-e25)</comment></element-citation></ref><ref id="bb0090"><label>18</label><element-citation publication-type="journal" id="rf0090"><person-group person-group-type="author"><name><surname>Sheikh</surname><given-names>A.</given-names></name><name><surname>Al-Taher</surname><given-names>A.</given-names></name><name><surname>Al-Nazawi</surname><given-names>M.</given-names></name><name><surname>Al-Mubarak</surname><given-names>A.I.</given-names></name><name><surname>Kandeel</surname><given-names>M.</given-names></name></person-group><article-title>Analysis of preferred codon usage in the coronavirus N genes and their implications for genome evolution and vaccine design</article-title><source>J. Virol. Methods</source><volume>277</volume><year>2020</year><object-id pub-id-type="publisher-id">113806</object-id></element-citation></ref><ref id="bb0095"><label>19</label><element-citation publication-type="journal" id="rf0095"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name></person-group><article-title>SARS-CoV protease inhibitors design using virtual screening method from natural products libraries</article-title><source>J. Comput. Chem.</source><volume>26</volume><year>2005</year><fpage>484</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">15693056</pub-id></element-citation></ref><ref id="bb0100"><label>20</label><element-citation publication-type="journal" id="rf0100"><person-group person-group-type="author"><name><surname>Sirois</surname><given-names>S.</given-names></name><name><surname>Wei</surname><given-names>D.-Q.</given-names></name><name><surname>Du</surname><given-names>Q.</given-names></name><name><surname>Chou</surname><given-names>K.-C.</given-names></name></person-group><article-title>Virtual screening for SARS-CoV protease based on KZ7088 pharmacophore points</article-title><source>J. Chem. Inf. Comput. Sci.</source><volume>44</volume><year>2004</year><fpage>1111</fpage><lpage>1122</lpage><pub-id pub-id-type="pmid">15154780</pub-id></element-citation></ref><ref id="bb0105"><label>21</label><element-citation publication-type="journal" id="rf0105"><person-group person-group-type="author"><name><surname>ElHefnawi</surname><given-names>M.</given-names></name><name><surname>ElGamacy</surname><given-names>M.</given-names></name><name><surname>Fares</surname><given-names>M.</given-names></name></person-group><article-title>Multiple virtual screening approaches for finding new Hepatitis c virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors</article-title><source>BMC Bioinf. BioMed Central</source><year>2012</year><fpage>S5</fpage></element-citation></ref><ref id="bb0110"><label>22</label><element-citation publication-type="journal" id="rf0110"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Z.</given-names></name><name><surname>Khaliq</surname><given-names>M.</given-names></name><name><surname>Suk</surname><given-names>J.-E.</given-names></name><name><surname>Patkar</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Kuhn</surname><given-names>R.J.</given-names></name></person-group><article-title>Antiviral compounds discovered by virtual screening of small&#x02212; molecule libraries against dengue virus E protein</article-title><source>ACS Chem. Biol.</source><volume>3</volume><year>2008</year><fpage>765</fpage><lpage>775</lpage><pub-id pub-id-type="pmid">19053243</pub-id></element-citation></ref><ref id="bb0115"><label>23</label><element-citation publication-type="journal" id="rf0115"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>U.</given-names></name><name><surname>Varadwaj</surname><given-names>P.K.</given-names></name></person-group><article-title>Flavonoids as multi-target inhibitors for proteins associated with Ebola virus: in silico discovery using virtual screening and molecular docking studies</article-title><source>Interdiscip. Sci. Comput. Life Sci.</source><volume>8</volume><year>2016</year><fpage>132</fpage><lpage>141</lpage></element-citation></ref><ref id="bb0120"><label>24</label><element-citation publication-type="journal" id="rf0120"><person-group person-group-type="author"><name><surname>Crotty</surname><given-names>S.</given-names></name><name><surname>Maag</surname><given-names>D.</given-names></name><name><surname>Arnold</surname><given-names>J.J.</given-names></name><name><surname>Zhong</surname><given-names>W.</given-names></name><name><surname>Lau</surname><given-names>J.Y.</given-names></name><name><surname>Hong</surname><given-names>Z.</given-names></name></person-group><article-title>The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen</article-title><source>Nat. Med.</source><volume>6</volume><year>2000</year><fpage>1375</fpage><lpage>1379</lpage><pub-id pub-id-type="pmid">11100123</pub-id></element-citation></ref><ref id="bb0125"><label>25</label><element-citation publication-type="journal" id="rf0125"><person-group person-group-type="author"><name><surname>Koren</surname><given-names>G.</given-names></name><name><surname>King</surname><given-names>S.</given-names></name><name><surname>Knowles</surname><given-names>S.</given-names></name><name><surname>Phillips</surname><given-names>E.</given-names></name></person-group><article-title>Ribavirin in the treatment of SARS: a new trick for an old drug?</article-title><source>CMAJ</source><volume>168</volume><year>2003</year><fpage>1289</fpage><lpage>1292</lpage><pub-id pub-id-type="pmid">12743076</pub-id></element-citation></ref><ref id="bb0130"><label>26</label><element-citation publication-type="journal" id="rf0130"><person-group person-group-type="author"><name><surname>McKeage</surname><given-names>K.</given-names></name><name><surname>Keam</surname><given-names>S.J.</given-names></name></person-group><article-title>Telbivudine</article-title><source>Drugs</source><volume>70</volume><year>2010</year><fpage>1857</fpage><lpage>1883</lpage><pub-id pub-id-type="pmid">20836578</pub-id></element-citation></ref><ref id="bb9000"><label>27</label><element-citation publication-type="journal" id="rf4435"><person-group person-group-type="author"><name><surname>Friesner</surname><given-names>R.A.</given-names></name><name><surname>Jay</surname><given-names>J.</given-names></name><name><surname>Murphy</surname><given-names>T.A.</given-names></name><name><surname>Halgren</surname><given-names>J.J.</given-names></name><name><surname>Klicic</surname><given-names>D.T.</given-names></name><name><surname>Mainz</surname><given-names>M.P.</given-names></name><name><surname>Repasky et al.</surname></name></person-group><article-title>Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy</article-title><source>J. Med. Chem.</source><volume>47</volume><issue>7</issue><year>2004</year><fpage>1739</fpage><lpage>1749</lpage><pub-id pub-id-type="pmid">15027865</pub-id></element-citation></ref><ref id="bb8000"><label>28</label><element-citation publication-type="journal" id="rf1235"><person-group person-group-type="author"><name><surname>Halgren</surname><given-names>T.A.</given-names></name><name><surname>Murphy</surname><given-names>R.B.</given-names></name><name><surname>Friesner</surname><given-names>R.A.</given-names></name><name><surname>Beard</surname><given-names>H.S.</given-names></name><name><surname>Frye</surname><given-names>L.L.</given-names></name><name><surname>Pollard</surname><given-names>W.T.</given-names></name><name><surname>Banks</surname><given-names>J.L.</given-names></name></person-group><article-title>Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening</article-title><source>J. Med. Chem.</source><volume>47</volume><issue>7</issue><year>2004</year><fpage>1750</fpage><lpage>1759</lpage><pub-id pub-id-type="pmid">15027866</pub-id></element-citation></ref></ref-list><ack id="ac0005"><sec id="s0050"><title>Acknowledgments</title><p id="p0125">The authors acknowledge the <funding-source id="gts0005"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100004686</institution-id><institution>Deanship of Scientific Research, King Faisal University</institution></institution-wrap></funding-source> for the financial support under Research Groups track (Grant No. 1811016).</p></sec><sec sec-type="data-availability" id="s0055"><title>Data availability</title><p id="p0130">All data are within the manuscript and the supplementary materials.</p></sec><sec id="s0060"><title>Declaration of competing interest</title><p id="p0135">The authors declare no conflict of interest.</p></sec></ack></back></article>